HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Store Brand Cough/Cold OTCs, Alterna Conditioners Among Recent Recalls

Executive Summary

Sun Pharmaceutical, P&L Developments and Preferred Pharmaceutical made OTCs for customers including CVS, Target and Walgreens. Latest updates to FDA recalls database also includes polypeptide- and colostrum-containing immunity support supplements made by APS BioGroup and Alterna anti-aging, moisture-replenishing conditioning milk and cream marketed by Henkel Corp.

You may also be interested in...



Else Nutrition Takes 'Clean Label' Into Infant Formula, Toddler Beverage Market

Else Nutrition will be one of the first companies to market baby and toddler formula and a children’s beverage without dairy or soy while containing a few core ingredients, says CEO Hamutal Yitzhak. Products will debut in North America and Europe in 2020.

Clear Eyes Recall Adds Clarity To Extent Of Impact From Altaire Sterility Concerns

Number of containers recalled varies from nearly 6.7m bottles of Clear Eyes Redness Relief to 1,752 bottles of brand's Maximum Itchy Eye Relief. Updates to FDA database also include recalls of private label/store brand OTCs as agency finds more problems at manufacturers providing drugs for drug store chains, other retailers and distributors.

Infant Formula Woes Turn Perrigo's Q2 Sour Despite Solid Americas’ OTC Sales

Perrigo reports 4% Q2 sales growth for OTC drugs in the Americas region was offset by nearly 15% drop in infant formula sale. Total consumer sales in the Americas slipped 2.5% to $582m, but CEO Murray Kessler says brighter days are ahead on benefits from Ranir oral care acquisition.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel